Clicky

AKESO INC. O.N.(4RY) News

Date Title
Jul 28 Could bispecifics unseat Keytruda from its oncology throne?
Jul 28 NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
Jul 24 Exploring Three High Growth Tech Stocks In Asia
Jul 24 Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer
Jul 16 3 Asian Growth Companies With High Insider Ownership And 58% Earnings Growth
Jul 16 Asian Stocks Estimated To Be Trading At Discounts Of Up To 26.6%
Jul 16 Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
Jul 13 China Biotech’s Stunning Advance Is Changing the World’s Drug Pipeline
Jul 3 Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports
Jul 3 Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy
Jun 16 Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
Jun 2 Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal
Apr 25 Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
Apr 25 Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab
Apr 25 FDA approves Akeso’s monoclonal antibody for nasopharyngeal carcinoma
Apr 25 Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma
Apr 24 Akeso and Summit notch another Phase III win with their Keytruda competitor
Apr 23 Why Is Summit Therapeutics Stock Soaring On Wednesday?
Apr 23 Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy
Feb 14 Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases